Items Tagged ‘Mantle Cell Non-Hodgkin’s Lymphoma’

May 31, 2018

FDA Grants Approval of Calquence for the Treatment of Mantle Cell Lymphoma

By

The US Food and Drug Administration (FDA) has granted approval to Calquence (acalabrutinib) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Calquence is a highly-selective, potent Bruton tyrosine kinase (BTK) inhibitor being evaluated for the treatment of multiple B-cell cancers. About mantle cell lymphoma Mantle […]

View full entry

Tags: Acalabrutinib, Bruton tyrosine kinase (BTK) inhibitor, Calquence, Mantle Cell Non-Hodgkin's Lymphoma, MCL, News, Non-Hodgkin's Lymphoma, t mantle cell lymphoma, treatmen


November 6, 2017

FDA approves Calquence Treatment for Treatment of Mantle Cell Lymphoma

By

The U.S. Food and Drug Administration has granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.  Mantle cell lymphoma is a particularly aggressive cancer and new treatments are needed for patients who have not responded to treatment or have relapsed, Mantle […]

View full entry

Tags: Calquence acalabrutinib, Lymphoma, mantle cell lymphoma, Mantle Cell Non-Hodgkin's Lymphoma, News, Non-Hodgkin's Lymphoma